golimumab vs infliximab-dyyb (Zymfentra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

golimumab · Simponi

Marketed by Johnson & Johnson

Phase 2 in Crohn's Diseasemonoclonal antibody (fully human IgG1)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03945019 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.

Next expected readout: December 2026 · NCT06064864 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointgolimumabinfliximab-dyyb (Zymfentra)
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

golimumab
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (induction)

golimumab
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported

Clinical remission (maintenance)

golimumab
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (maintenance)

golimumab
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

golimumab: registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

infliximab-dyyb (Zymfentra): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

golimumab · Simponi

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Reliable signal

NCT01863771 · Phase 3 · completed

Design meets the 'strong' bar: randomized, double-blind (participant and investigator masked), placebo-controlled, phase 3, with a hard clinical endpoint (Mayo score-based clinical response); the primary comparison was clearly met in the favorable direction (18/32 vs 6/31, non-overlapping 95% CIs).

Reported efficacy

Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) (met)

Result source: NCT01863771

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT04205643 · Phase 3 · completed

The trial was randomized, quadruple-blind, and placebo-controlled, with 548 participants enrolled and 438 participants included in the reported maintenance analysis. The hard clinical primary endpoint—clinical remission by the modified Mayo score at week 54—was met, with 127 of 294 participants receiving CT-P13 versus 30 of 144 receiving placebo (p<0.0001).

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointgolimumabinfliximab-dyyb (Zymfentra)
Clinical remission (induction)17.9% vs 6.4%+11.5 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 17.8% vs 6.4% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · secondary NCT00487539
—Not reported
Clinical remission (maintenance)—Trial running · NCT03596645—Not reported
Clinical response (induction)54.9% vs 30.3%+24.6 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 51% vs 30.3% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · primary NCT00487539
—Not reported
Endoscopic improvement (induction)—Trial running · NCT03596645—Not reported
Corticosteroid-free remission (maintenance)23.2% vs 18.4%+4.8 vs placebo100 mg · wk 54 · n 82NCT00488631
1 other result
  • 28.2% vs 18.4% 50 mg · wk 54 · n 78 · Phase 3 · secondary NCT00488631
—Not reported

Clinical remission (induction)

golimumab
17.9% vs 6.4%+11.5 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 17.8% vs 6.4% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · secondary NCT00487539
infliximab-dyyb (Zymfentra)
—Not reported

Clinical remission (maintenance)

golimumab
—Trial running · NCT03596645
infliximab-dyyb (Zymfentra)
—Not reported

Clinical response (induction)

golimumab
54.9% vs 30.3%+24.6 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 51% vs 30.3% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · primary NCT00487539
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic improvement (induction)

golimumab
—Trial running · NCT03596645
infliximab-dyyb (Zymfentra)
—Not reported

Corticosteroid-free remission (maintenance)

golimumab
23.2% vs 18.4%+4.8 vs placebo100 mg · wk 54 · n 82NCT00488631
1 other result
  • 28.2% vs 18.4% 50 mg · wk 54 · n 78 · Phase 3 · secondary NCT00488631
infliximab-dyyb (Zymfentra)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-dyyb (Zymfentra): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. golimumab: 4 of 4 rows · infliximab-dyyb (Zymfentra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricgolimumab
Dropout rate
—100 mga
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
—100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.6%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—200 mg
NCT00488631 · Phase 3
29.2%100 mg
NCT00488631 · Phase 3 · combination
—100 mg - 200 mg
NCT00488631 · Phase 3
53.3%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg - 200 mg
NCT00488631 · Phase 3
—100 mg
NCT00488631 · Phase 3
44.8%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg
NCT00488631 · Phase 3
27.9%50 mg
NCT00488631 · Phase 3 · combination
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
1.2%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
0.9%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
4.2%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
7.1%Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
4.3%Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
23.7%
NCT02318667 · Phase 4 · registry result, not featured evidence
17.1%
NCT02092285 · Phase 4 · registry result, not featured evidence
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
6.9%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
—100 mga
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
—100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
6.3%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—200 mg
NCT00488631 · Phase 3
7.8%100 mg
NCT00488631 · Phase 3 · combination
—100 mg - 200 mg
NCT00488631 · Phase 3
12.3%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg - 200 mg
NCT00488631 · Phase 3
—100 mg
NCT00488631 · Phase 3
13%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg
NCT00488631 · Phase 3
7.8%50 mg
NCT00488631 · Phase 3 · combination
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
0.3%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
0.3%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
2.8%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
—Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
—Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
2.6%
NCT02318667 · Phase 4 · registry result, not featured evidence
3.4%
NCT02092285 · Phase 4 · registry result, not featured evidence
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
0%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
3.1%100 mga
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
10%100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
3.5%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.3%200 mg
NCT00488631 · Phase 3
14.3%100 mg
NCT00488631 · Phase 3 · combination
7.1%100 mg - 200 mg
NCT00488631 · Phase 3
15.6%100 mg
NCT00488631 · Phase 3 · monotherapy
0%100 mg - 200 mg
NCT00488631 · Phase 3
19.4%100 mg
NCT00488631 · Phase 3
14.8%100 mg
NCT00488631 · Phase 3 · monotherapy
25%100 mg
NCT00488631 · Phase 3
8.4%50 mg
NCT00488631 · Phase 3 · combination
24%50 mg - 100 mg
NCT00488631 · Phase 3
5.3%50 mg - 100 mg
NCT00488631 · Phase 3
11.8%50 mg
NCT00488631 · Phase 3
0%50 mg
NCT00488631 · Phase 3
4.5%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
3%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
4.2%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
9.5%Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
0%Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
10.5%
NCT02318667 · Phase 4 · registry result, not featured evidence
23.9%
NCT02092285 · Phase 4 · registry result, not featured evidence
1.4%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.2%Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
4.5%Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
0%Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
0%Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
100 mga
nasopharyngitis 53.1% (placebo 22.6%)
injection site erythema 15.6% (placebo 0%)
influenza 12.5% (placebo 3.2%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 26 more results
100 mg
nasopharyngitis 23.3% (placebo 22.6%)
colitis ulcerative 6.7% (placebo 6.5%)
upper respiratory tract inflammation 6.7% (placebo 0%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 11.8% (placebo 22.6%)
colitis ulcerative 4.9% (placebo 6.5%)
injection site erythema 3.5% (placebo 0%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
200 mg
colitis ulcerative 28.6% (placebo 18.6%)
gastroenteritis viral 28.6% (placebo 0%)
nasopharyngitis 28.6% (placebo 6.4%)
NCT00488631 · Phase 3
100 mg
nasopharyngitis 14.9% (placebo 6.4%)
colitis ulcerative 11.7% (placebo 18.6%)
headache 7.8% (placebo 9%)
NCT00488631 · Phase 3 · combination
100 mg - 200 mg
nasopharyngitis 21.4% (placebo 6.4%)
headache 14.3% (placebo 9%)
viral upper respiratory tract infection 14.3% (placebo 0%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 12.1% (placebo 18.6%)
nasopharyngitis 8.1% (placebo 6.4%)
arthralgia 7.2% (placebo 7.1%)
NCT00488631 · Phase 3 · monotherapy
100 mg - 200 mg
colitis ulcerative 30% (placebo 18.6%)
diarrhoea 20% (placebo 4.5%)
gastroenteritis 20% (placebo 1.9%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 23.7% (placebo 18.6%)
nasopharyngitis 16.4% (placebo 6.4%)
sinusitis 9% (placebo 1.9%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 10.9% (placebo 18.6%)
headache 9.6% (placebo 9%)
nasopharyngitis 7.4% (placebo 6.4%)
NCT00488631 · Phase 3 · monotherapy
100 mg
colitis ulcerative 25% (placebo 18.6%)
nasopharyngitis 14.3% (placebo 6.4%)
arthralgia 10.7% (placebo 7.1%)
NCT00488631 · Phase 3
50 mg
colitis ulcerative 16.2% (placebo 18.6%)
nasopharyngitis 9.1% (placebo 6.4%)
headache 8.4% (placebo 9%)
NCT00488631 · Phase 3 · combination
50 mg - 100 mg
nasopharyngitis 16% (placebo 6.4%)
pyrexia 16% (placebo 4.5%)
upper respiratory tract infection 12% (placebo 2.6%)
NCT00488631 · Phase 3
50 mg - 100 mg
colitis ulcerative 10.5% (placebo 18.6%)
dyspepsia 10.5% (placebo 1.3%)
upper respiratory tract infection 10.5% (placebo 2.6%)
NCT00488631 · Phase 3
50 mg
colitis ulcerative 18.3% (placebo 18.6%)
nasopharyngitis 10.8% (placebo 6.4%)
arthralgia 9.7% (placebo 7.1%)
NCT00488631 · Phase 3
50 mg
abdominal pain 100% (placebo 2.6%)
abdominal pain upper 100% (placebo 0.6%)
bite 100% (placebo 0%)
NCT00488631 · Phase 3
400 mg -> 200 mg
headache 4.5% (placebo 5.2%)
nausea 3.6% (placebo 1.8%)
pyrexia 3% (placebo 2.1%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
200 mg -> 100 mg
nasopharyngitis 3.9% (placebo 3.6%)
headache 3.3% (placebo 5.2%)
anaemia 2.4% (placebo 1.8%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
100 mg -> 50 mg
headache 7% (placebo 5.2%)
injection site erythema 4.2% (placebo 0%)
anaemia 2.8% (placebo 1.8%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
colitis ulcerative 10.5%
NCT02318667 · Phase 4 · registry result, not featured evidence
colitis ulcerative 13.7%
nasopharyngitis 9.8%
colitis 7.3%
NCT02092285 · Phase 4 · registry result, not featured evidence
anaemia 5.6%
colitis ulcerative 5.6%
headache 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 11.1%
anaemia 6.9%
upper respiratory tract infection 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
colitis ulcerative 8.5%
upper respiratory tract infection 8.5%
headache 4.2%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 7.5%
anaemia 3%
headache 3%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
anaemia 0%
colitis ulcerative 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 5.2%
anaemia 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 23 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

golimumab

Clinical Response 54.9% (n=257) vs 30.3% (n=251) placebo @ 6wk400 mg -> 200 mg
responder rate · % of participants
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 141 Participants as posted
show 4 more results
51% (n=253) vs 30.3% (n=251) placebo @ 6wk*200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 129 Participants as posted
49.7% (n=151) vs 31.2% (n=154) placebo @ 54wk*100 mg
NCT00488631 · Phase 3 · combination · converted to % from 75 Participants as posted
47% (n=151) vs 31.2% (n=154) placebo @ 54wk*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 71 Participants as posted
56.3% (n=32) vs 19.4% (n=31) placebo @ 54wk*
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 18 participants as posted
Clinical Remission 17.9% (n=257) vs 6.4% (n=251) placebo @ 6wk400 mg -> 200 mg
responder rate · % of participants
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 46 Participants as posted
show 2 more results
17.8% (n=253) vs 6.4% (n=251) placebo @ 6wk*200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 45 Participants as posted
50% (n=32) vs 6.5% (n=31) placebo*
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 16 participants as posted
Mucosal Healing 42.4% (n=151) vs 26.6% (n=154) placebo100 mg
event count · % of participants
NCT00488631 · Phase 3 · combination · converted to % from 64 Participants as posted
show 2 more results
41.7% (n=151) vs 26.6% (n=154) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 63 Participants as posted
59.4% (n=32) vs 16.1% (n=31) placebo*
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 19 participants as posted
Sustained Clinical Remission 27.8% (n=151) vs 15.6% (n=154) placebo100 mg
responder rate · % of participants
NCT00488631 · Phase 3 · combination · converted to % from 42 Participants as posted
show 3 more results
38.9% (n=54) vs 24.1% (n=54) placebo*100 mg
NCT00488631 · Phase 3 · combination · converted to % from 21 Participants as posted
23.2% (n=151) vs 15.6% (n=154) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 35 Participants as posted
36.5% (n=52) vs 24.1% (n=54) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 19 Participants as posted
Corticosteroid-free Clinical Remission 23.2% (n=82) vs 18.4% (n=87) placebo @ 54wk100 mg
responder rate · % of participants
NCT00488631 · Phase 3 · combination · converted to % from 19 Participants as posted
show 1 more result
28.2% (n=78) vs 18.4% (n=87) placebo @ 54wk*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 22 Participants as posted
Endoscopic Improvement 45.1% (n=257) vs 28.7% (n=251) placebo @ 6wk400 mg -> 200 mg
event count · % of participants
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 116 Participants as posted
show 1 more result
42.3% (n=253) vs 28.7% (n=251) placebo @ 6wk*200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 107 Participants as posted
IBDQ 26.9 vs 14.8 placebo score @ 6wk400 mg -> 200 mg
absolute change · score
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
show 1 more result
27 vs 14.8 placebo score @ 6wk200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
Partial Mayo 24.9% (n=205) @ 54wk
responder rate · % of participants
No placebo or comparator arm
NCT02092285 · Phase 4 · registry result, not featured evidence
Clinical Response 61.1% (n=72) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
show 1 more result
83.1% (n=71) @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
Clinical Remission 22.2% (n=72) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
show 1 more result
36.6% (n=71) @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: golimumab's landscape · infliximab-dyyb (Zymfentra)'s landscape